4/A: Neogenomics CFO Amends Filing After Reporting Error in Stock Transactions

Neogenomics CFO Jeffrey Scott Sherman amended a previous filing to correct the number of shares owned after a restricted stock unit vesting event.

Summary

• Neogenomics CFO Jeffrey Scott Sherman filed an amended Form 4 to correct a previous error in reporting his stock ownership.
• The amendment clarifies that on May 11, 2024, Mr. Sherman acquired 13,005 shares of common stock through the vesting of restricted stock units (RSUs).
• A portion of the shares, 3,167, were withheld to cover tax obligations at a price of $14.86 per share.
• After these transactions, Mr. Sherman directly owns 135,500 shares of Neogenomics common stock.
• The original filing on May 14, 2024, incorrectly reported the number of shares received upon vesting of the RSUs twice.

Sentiment

Score: 6

Explanation: The document is a routine correction of a filing error. While the error is a negative, the correction is a positive. Overall, the sentiment is neutral.

Negatives

• The need for an amended filing indicates an initial error in reporting stock transactions.

Risks

• Errors in reporting insider transactions can lead to scrutiny from regulators and investors.
• Inaccurate filings can erode investor confidence.

Industry Context

This filing is a routine disclosure of insider transactions, which is common for publicly traded companies. It is important for transparency and regulatory compliance.

Comparison to Industry Standards

• Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders in the US.
• Similar filings are made by executives at companies like Exact Sciences (EXAS) and Guardant Health (GH) when they have stock transactions.
• The need for an amendment is not uncommon, but it highlights the importance of accuracy in these filings.

Stakeholder Impact

• The correction of the filing ensures transparency for shareholders.
• The error could have caused confusion among investors if not corrected.

Key Dates

Keywords

Neogenomics, insider trading, Form 4, stock ownership, restricted stock units, RSU, CFO, Jeffrey Scott Sherman, amended filing